X-ray microanalysis of exocrine glands in animal models for cystic fibrosis.
Elemental distribution and ultrastructure of the submandibular gland, the parotid gland and the pancreas were investigated in three suggested animal models of the disease cystic fibrosis: the chronically reserpinized rat, the chronically isoproterenol-treated rat, and the chronically pilocarpine-treated rat. To elucidate the cellular mechanism underlying the effects of these treatments, chronic effects of specific alpha - and beta -adrenergic agonists, as well as acute effects of reserpine and various agonists were also investigated. Reserpine, isoproterenol, and pilocarpine cause an increase in the calcium concentration in submandibular gland acinar cells, due to an increased calcium content of the intracellular mucus. In the parotid gland, reserpine and isoproterenol cause a decrease of the calcium concentration in acinar cells, due to a lower calcium content of the zymogen granules. In the submandibular gland, a decreased cellular Na concentration was noted after chronic treatment with isoproterenol or pilocarpine, and after a single dose of reserpine or isoproterenol. Ultrastructural changes in the exocrine glands investigated included excessive accumulation of intracellular secretory material and formation of abnormal uncondensed secretion granules. A common pattern in the 'animal models' appears to be (1) inhibition of secretion resulting in intracellular accumulation of secretory material, (2) synthesis of secretory macromolecules with altered cation-binding properties.
Müller
R M
RM
Roomans
G M
GM
D000318:Adrenergic beta-Agonists / Q000633:toxicity; D000818:Animals; D003550:Cystic Fibrosis / Q000473:pathology*; D003594:Cytoplasmic Granules / Q000648:ultrastructure; D004195:Disease Models, Animal; D004577:Electron Probe Microanalysis / Q000379:methods; D005260:Female; D006801:Humans; D007545:Isoproterenol / Q000633:toxicity; D010179:Pancreas / Q000187:drug effects / Q000473:pathology / Q000648:ultrastructure*; D010306:Parotid Gland / Q000648:ultrastructure*; D010656:Phenylephrine / Q000633:toxicity; D010862:Pilocarpine / Q000633:toxicity; D011217:Practolol / Q000031:analogs & derivatives / Q000633:toxicity; D011294:Prenalterol; D051381:Rats; D011919:Rats, Inbred Strains; D012110:Reserpine / Q000633:toxicity; D012469:Salivary Glands / Q000187:drug effects / Q000473:pathology; D013363:Submandibular Gland / Q000648:ultrastructure*; D013726:Terbutaline / Q000633:toxicity
D000318:Adrenergic beta-Agonists; D010862:Pilocarpine; D010656:Phenylephrine; D012110:Reserpine; D007545:Isoproterenol; D011294:Prenalterol; D013726:Terbutaline; D011217:Practolol